Finance Watch: VC Fundraising Dips In Q2, But Mega-Deal Pace Is Strong

First Half Of 2022 Venture Cash Equals 2019 Full-Year Total

Private Company Edition: The amount of venture capital raised by biopharma firms fell but individual companies grabbed a lot of cash, making for a remarkable Q2 relative to pre-pandemic times. Recent Q3 rounds includes Frontera’s $160m series B. Also, Oxford Science Enterprises added €250m to its fund.

Finance Watch Private Company
• Source: Shutterstock

Venture capital fundraising by biopharmaceutical firms in the second quarter was a mixed bag, according to Venture Monitor data from Pitchbook and the National Venture Capital Association (NVCA), which reported a sharp drop from Q1 to Q2 in terms of both the amount of money raised and the number of companies that closed VC rounds, but a big gain in the average deal size.

In the second quarter, 210 biopharma companies raised $6.1bn, down from 302 companies that raised $11.6bn in the first quarter,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.